Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: Results from a prospective study before and after surgery

European Journal of Endocrinology

Volumn 163, Issue 5, 2010, Pages 783-791

  Manetti, Luca ^a   Bogazzi, Fausto ^a   Giovannetti, Clara ^a   Raffaelli, Valentina ^a   Genovesi, Maura ^a   Pellegrini, Giovanni ^b   Ruocco, Lucia ^b   Iannelli, Aldo ^a   Martino, Enio ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CORTICOTROPIN; D DIMER; FIBRINOGEN; HYDROCORTISONE; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; THROMBIN ANTITHROMBIN COMPLEX; VITRONECTIN; VON WILLEBRAND FACTOR;

ADRENAL CORTEX ADENOMA; ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD GROUP ABO SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CUSHING SYNDROME; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYDROCORTISONE URINE LEVEL; LUNG EMBOLISM; MALE; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; VENOUS THROMBOEMBOLISM; BLOOD; BLOOD CLOTTING TEST; COMPARATIVE STUDY; INCIDENCE; MIDDLE AGED; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE;

ADULT; AGED; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CUSHING SYNDROME; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 77957836538     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0583     Document Type: Article

References (30)

1. Mancini T, Kola B, Mantero F, Boscaro M & Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clinical Endocrinology 2004 61 768-777. (doi:10.1111/j.1365- 2265.2004.02168.x)
2. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A & Boscaro M. Diagnosis and complications of Cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2003 88 5593-5602. (doi:10.1210/jc.2003-030871) (Pubitemid 38033020)
3. Arnaldi G, Mancini T, Polenta B & Boscaro M. Cardiovascular risk in Cushing's syndrome. Pituitary 2004 7 253-256. (doi:10.1007/s11102-005-1172-7)
4. Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Akeen MO, Voormolen JH & Romijn JA. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for non-functioning pituitary macroadenoma. Journal of Clinical Endocrinology and Metabolism 2007 92 976-981. (doi:10.1210/jc.2006-2112) (Pubitemid 46465672)
5. Small M, Lowe GD, Forbes CD & Thomson JA. Thromboembolic complications in Cushing's syndrome. Clinical Endocrinology 1983 19 503-511. (doi:10.1111/j.1365-2265.1983.tb00025.x)
6. La Brocca A, Terzolo M, Pia A, Paccotti P, De Giuli P & Angeli A. Recurrent thromboembolism as a hallmark of Cushing's syndrome. Journal of Endocrinological Investigation 1997 20 211-214. (Pubitemid 27289381)
7. Semple PL & Laws ER Jr. Complications in a contemporary series of patients who underwent transsphenoidal surgery for Cushing's disease. Journal of Neurosurgery 1999 91 175-179. (doi:10.3171/jns.1999.91.2.0175)
8. Sudhakar N, Ray A & Vafidis JA. Complications after transsphenoidal surgery: our experience and a review of the literature. British Journal of Neurosurgery 2004 18 507-512. (doi:10.1080/02688690400012459)
9. Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM & Girolami A. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 3662-3666. (doi:10.1210/jc.87.8.3662)
10. Dal Bo Zanon R, Fornasiero L, Boscaro M, Cappellato G, Fabris F & Girolami A. Increased factor VIII associated activities in Cushing's syndrome: a probable hypercoagulable state. Thrombosis and Haemostasis 1982 47 116-117. (Pubitemid 12158364)
11. Patrassi GM, Sartori MT, Viero ML, Scarano L, Boscaro M & Girolami A. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagulation & Fibrinolysis 1992 3 789-793. (doi:10.1097/00001721-199212000-00013)
12. Fatti LM, Bottasso B, Invitti C, Coppola R, Cavagnini F & Mannucci PM. Marker of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. Journal of Endocrinological Investigation 2000 23 145-150.
13. Ikkala E, Myllylä G, Pelkonen R, Rasi V, Viinikka L & Ylikorkala O. Haemostatic parameters in Cushing's syndrome. Acta Medica Scandinavica 1985 217 507-511. (doi:10.1111/j.0954-6820.1985.tb03254.x)
14. Patrassi GM, Dal Bo Zanon R, Boscaro M, Martinelli S & Girolami A. Further studies on the hypercoagulable state of patients with Cushing's syndrome. Thrombosis and Haemostasis 1985 30 518-520. (Pubitemid 16255686)
15. Patrassi GM, Sartori MT, Livi U, Casonato A, Danesin C, Vettore S & Girolami A. Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation. Transplantation 1997 64 1610-1614. (doi:10.1097/00007890-199712150-00021)
16. Ambrosi B, Sartorio A, Pizzocaro A, Passini E, Bottasso B & Federici A. Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma. Experimental and Clinical Endocrinology and Diabetes 2000 108 294-298. (doi:10.1055/s-2000-8000)
17. Squizzato A, Gerdes VEA, Ageno W & Buller HR. The coagulation system in endocrine disorders: a narrative review. Internal and Emergency Medicine 2007 2 76-83. (doi:10.1007/s11739-007-0026-X)
18. Kastelan D, Dusek T, Kraljevic I, Polasek O, Giljevic Z, Solak M, Zupanic Salek S, Jelcic J, Aganovic I & Korsic M. Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 2009 36 70-74. (doi:10.1007/s12020-009-9186-y)
19. Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O & Onder Ersoz H. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. Journal of Endocrinological Investigation 2009 32 169-174.
20. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM & Montori VM. The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2008 93 1526-1540. (doi:10.1210/jc.2008-0125)
21. Boscaro M & Arnaldi G. Approach to the patient with possible Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2009 94 3121-3131. (doi:10.1210/jc.2009-0612)
22. Franchini M, Lippi G, Manzato F, Vescovi PP & Targher G. Hemostatic abnormalities in endocrine and metabolic disorders. European Journal of Endocrinology 2010 162 439-451. (doi:10.1530/EJE-09-0958)
23. Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MB, Fliers E, Gerdes VEA, Büller HR & Brandjes PM. Hypercoagulable state in Cushing's syndrome: a systematic review. Journal of Clinical Endocrinology and Metabolism 2009 94 2743-2750. (doi:10.1210/jc.2009-0290)
24. Healy AM & Gelehrter TD. Induction of plasminogen activator inhibitor-1 in HepG2 human hepatoma cells by mediators of the acute phase response. Journal of Biological Chemistry 1994 269 19095-19100.
25. Halleux CM, Declerck PJ, Tran SL, Detry R & Brichard SM. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. Journal of Clinical Endocrinology and Metabolism 1999 84 4097-4105. (doi:10.1210/jc.84.11.4097)
26. Casonato A, Pontara E, Boscaro M, Sonino N, Sartorello F, Ferrasin S & Girolami A. Abnormalities of von Willebrand factor are also part of the thrombotic state of Cushing's syndrome. Blood Coagulation and Fibrinolysis 1999 10 145-151. (doi:10.1097/00001721-199904000-00006)
27. Casonato A, Daidone V, Sartorello F, Albiger N, Romualdi C, Mantero F, Pagnan A & Scaroni C. Polymorfisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome. British Journal of Haematology 2008 140 230-235. (doi:10.1111/j.1365-2141.2007.06907.x)
28. Denis CV. von Willebrand factor in vascular pathophysiology. Pathologie et Biologie 2003 51 395-396. (doi:10.1016/S0369-8114(03)00025-7)
29. Bayston TA & Lane DA. Antithrombin: molecular basis of deficiency. Thrombosis and Haemostasis 1997 78 339-343.
30. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA & Boscaro M. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2008 93 2454-2462. (doi:10.1210/jc.2007-2734)